Association Between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis
DOI: https://doi.org/10.2147/CLEP.S403314
2023-06-05
Clinical Epidemiology
Abstract:Qianjia Sun, 1, 2, &ast Tingjing Zhang, 3, &ast Laeeqa Manji, 4 Yashu Liu, 1, 2 Qing Chang, 1, 2 Yuhong Zhao, 1, 2 Yang Ding, 5, 6 Yang Xia 1, 2 1 Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China; 2 Key Laboratory of Precision Medical Research on Major Chronic Disease, Shenyang, People's Republic of China; 3 School of Public Health, Wannan Medical College, Wuhu, People's Republic of China; 4 International Educational School, China Medical University, Shenyang, People's Republic of China; 5 Department of Infectious Diseases, Shengjing Hospital of China Medical University, China Medical University, Shenyang, People's Republic of China; 6 Diagnosis and Treatment Centre for Liver Diseases of Liaoning Province, Shenyang, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yang Xia, Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, No. 36, San Hao Street, Shenyang, Liaoning, 110004, People's Republic of China, Tel +86 24-96615-13650, Email ; Yang Ding, Department of Infectious Diseases, Shengjing Hospital of China Medical University, No. 36, San Hao Street, Shenyang, Liaoning, 110004, People's Republic of China, Tel +86 24-96615-62211, Email Objective: Recent epidemiological evidence shows that there is an association between serum uric acid (SUA) levels and nonalcoholic fatty liver disease (NAFLD). The purpose of this meta-analysis is to summarize all available evidence and assess the associations between SUA levels and NAFLD. Methods: Using two databases, Web of Science and PubMed, observational studies were applied from the establishment of the databases to June 2022. We used a random effect model to construct the pooled odds ratio (OR) and 95% confidence interval (CI) to appraise the association between SUA levels and NAFLD. The Begg's test was conducted to appraise publication bias. Results: A total of 50 studies were included, involving 2,079,710 participants (719,013 NAFLD patients). The prevalence and incidence rates (95% CIs) of NAFLD in the patients with hyperuricemia were 65% (57– 73%) and 31% (20– 41%), respectively. Compared to participants with lower levels of SUA, the pooled OR (95% CI) of NAFLD in those with higher levels of SUA was 1.88 (95% CI: 1.76– 2.00). In the subgroup analyses, we found that SUA levels were positively associated with NAFLD in all subgroups, according to study design, study quality, sample size, sex, comparison, age, or country. Conclusion: This meta-analysis shows that increased SUA levels are positively associated with NAFLD. The results suggested that reducing SUA levels can be a potential strategy for the prevention of NAFLD. Registration Number: PROSPERO-CRD42022358431. Keywords: serum uric acid, nonalcoholic fatty liver disease, meta-analysis, updated One of the most prevalent chronic liver illnesses globally is non-alcoholic fatty liver disease (NAFLD). In 2020, NAFLD evolved into metabolic dysfunction-associated fatty liver disease (MAFLD). 1 Although emerging studies have explored the associations between MAFLD and health outcomes over the past two years, there have been limited studies that investigate the associations between SUA and MAFLD. Additionally, there are differences in the definitions of NAFLD and MAFLD. MAFLD is defined as the evidence of overweight/obesity, the existence of type 2 diabetes or metabolic disorder on the basis of fatty liver. 1 NAFLD refers to liver steatosis>5% found by imaging or histology after excluding significant recent drinking and other liver diseases with known causes. 2 Therefore, based on the current available data, we summarized the associations between SUA and NAFLD in this meta-analysis. In 2018, the prevalence of NAFLD was about 25%. 3 NAFLD may develop into a series of advanced liver diseases such as fibrosis, cirrhosis and liver cancer. 4 Moreover, NAFLD is associated with other diseases, such as diabetes, hypertension, and cerebrovascular diseases. 5,6 Considering the disease burden caused by NAFLD and its high prevalence, it is necessary to determine its risk factors. The primary by-product of purine metabolism in the body is serum uric acid (SUA). Previous articles found that the increase in SUA levels acts an independent risk factor for NAFLD and may be utilized as an indicator to assess the NAFLD risk, 7–10 and that the prevalen -Abstract Truncated-
public, environmental & occupational health